Recently the Chinese Ministry of Health declared that 93 million people wer.e chronically infected with hepatitis B virus （HBV） in China. Four nucleotide analogues （NAs） are currently approved for the treatment of...Recently the Chinese Ministry of Health declared that 93 million people wer.e chronically infected with hepatitis B virus （HBV） in China. Four nucleotide analogues （NAs） are currently approved for the treatment of HBV infection, i.e., lamivudine （LAM）, adefovir （ADV）, entecavir （ETV）, and telbivudine （L-dT）. In contrast to therapeutic benefits, prolonged use of NAs increases the emergence of drug-resistant mutations in the HBV reverse transcriptase （RT） domain, leading to a progressive accumulation of NAs-resistant patients. Especially, LAM-refractory patients are prone to develop cross-resistance to other NAs. Novel anti-HBV drugs that are able to deal with the cross-resistance are needed in the clinic. Tenofovir （TDF）, which was recently approved in Europe and United States of America, has potential to be such a drug. Clinical trials have proven its high potency for inhibiting HBV replication in HBV-infected patients,展开更多
基金The study was supported by the grants from the National Key Basic Research Developing Project （No. 2007CB512803）, the Beijing Science and Technology Project （No. Z07050700690702）, and partly by the Beijing Natural Science Foundation （No. 7091006）.Acknowledgement： The authors gratefully acknowledge experimental participation of technicians at Viral Hepatitis Research Laboratory as follows： DAI Jiu-zeng, LI Le, YAO Zeng-tao.
文摘Recently the Chinese Ministry of Health declared that 93 million people wer.e chronically infected with hepatitis B virus （HBV） in China. Four nucleotide analogues （NAs） are currently approved for the treatment of HBV infection, i.e., lamivudine （LAM）, adefovir （ADV）, entecavir （ETV）, and telbivudine （L-dT）. In contrast to therapeutic benefits, prolonged use of NAs increases the emergence of drug-resistant mutations in the HBV reverse transcriptase （RT） domain, leading to a progressive accumulation of NAs-resistant patients. Especially, LAM-refractory patients are prone to develop cross-resistance to other NAs. Novel anti-HBV drugs that are able to deal with the cross-resistance are needed in the clinic. Tenofovir （TDF）, which was recently approved in Europe and United States of America, has potential to be such a drug. Clinical trials have proven its high potency for inhibiting HBV replication in HBV-infected patients,
